Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
Summary Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.Methods A total of 173 patients with confirmed SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during the hospitalization period were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2 using immunoassays. The dynamics of antibodies with the progress and severity of disease was analyzed.Results Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1% (161/173), 82.7% (143/173) and 64.7% (112/173), respectively. Twelve patients who had not seroconverted were those only blood samples at the early stage of illness were collected. The seroconversion sequentially appeared for Ab, IgM and then IgG, with a median time of 11, 12 and 14 days, respectively. The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset. In contrast, the positive rate of RNA decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15 to 39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 patients (p < 0.001), even in early phase of 1-week since onset (p = 0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p = 0.006).Conclusions The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 28. Dez. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Juanjuan [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.03.02.20030189 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI000752592 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI000752592 | ||
| 003 | DE-627 | ||
| 005 | 20230429090130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200313s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.03.02.20030189 |2 doi | |
| 035 | |a (DE-627)XBI000752592 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.03.02.20030189 | ||
| 035 | |a (biorXiv)10.1101/2020.03.02.20030189 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Zhao, Juanjuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.Methods A total of 173 patients with confirmed SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during the hospitalization period were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2 using immunoassays. The dynamics of antibodies with the progress and severity of disease was analyzed.Results Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1% (161/173), 82.7% (143/173) and 64.7% (112/173), respectively. Twelve patients who had not seroconverted were those only blood samples at the early stage of illness were collected. The seroconversion sequentially appeared for Ab, IgM and then IgG, with a median time of 11, 12 and 14 days, respectively. The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset. In contrast, the positive rate of RNA decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15 to 39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 patients (p < 0.001), even in early phase of 1-week since onset (p = 0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p = 0.006).Conclusions The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients. | ||
| 700 | 1 | |a Yuan, Quan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Haiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Xuejiao |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tingdong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jinxiu |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Congming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fuxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a He, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhiyong |e verfasserin |4 aut | |
| 700 | 1 | |a He, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tianying |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Shengxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Ningshao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 28. Dez. |
| 773 | 1 | 8 | |g year:2020 |g day:28 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/cid/ciaa344 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.03.02.20030189 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 28 |c 12 | ||
| 953 | |2 045F |a 570 | ||